Cholesterol Clinical Trials 2023

Browse 54 Cholesterol Medical Studies Across 274 Cities

12 Phase 3 Trial · 443 Cholesterol Clinics

Reviewed by Michael Gill, B. Sc.
10 Cholesterol Clinical Trials Near Me
Top Hospitals for Cholesterol Clinical Trials
Image of Novartis Investigative Site in Florida.
Novartis Investigative Site
Boca Raton
3Active Trials
3All Time Trials for Cholesterol
2021First Cholesterol Trial
Image of Novartis Investigative Site in Alabama.
Novartis Investigative Site
Birmingham
2Active Trials
1All Time Trials for Cholesterol
2023First Cholesterol Trial
Image of Novartis Investigative Site in Virginia.
Novartis Investigative Site
Richmond
2Active Trials
2All Time Trials for Cholesterol
2017First Cholesterol Trial
Image of Novartis Investigative Site in Louisiana.
Novartis Investigative Site
Shreveport
2Active Trials
1All Time Trials for Cholesterol
2023First Cholesterol Trial
Image of Novartis Investigative Site in Georgia.
Novartis Investigative Site
Atlanta
2Active Trials
1All Time Trials for Cholesterol
2021First Cholesterol Trial
Top Cities for Cholesterol Clinical Trials
Image of Cincinnati in Ohio.
Cincinnati
12Active Trials
Cincinnati Children's Hospital Medical CenterTop Active Site
Image of Boca Raton in Florida.
Boca Raton
7Active Trials
Novartis Investigative SiteTop Active Site
Cholesterol Clinical Trials by Phase of TrialCholesterol Clinical Trials by Age Group
< 18 Cholesterol Clinical Trials
3Active Cholesterol Clinical Trials
Most Recent Cholesterol Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Top Treatments for Cholesterol Clinical Trials
Treatment Name
Active Cholesterol Clinical Trials
All Time Trials for Cholesterol
First Recorded Cholesterol Trial
Treatment
5
5
1995
Inclisiran
4
12
2017
MK-0616
2
4
2022
Obicetrapib
2
5
2021
Dietitian-Assisted DASH groceries
2
2
2022
Recently Completed Studies with FDA Approved Treatments for Cholesterol
Treatment
Year
Sponsor
MK-0616
2022
Merck Sharp & Dohme Corp.
lerodalcibep
2021
LIB Therapeutics LLC
Evinacumab
2020
Regeneron Pharmaceuticals
lerodalcibep
2019
LIB Therapeutics LLC
Inclisiran Sodium
2019
Novartis
Ezetimibe
2018
Sanofi
evinacumab
2018
Regeneron Pharmaceuticals

What Are Cholesterol Clinical Trials?

The liver produces cholesterol, a waxy, fatty substance in the bloodstream and the body's cells. In addition to being necessary for forming tissues, hormones, bile acid, cell walls, and vitamin D, cholesterol is vital for staying healthy.

The two primary sources of cholesterol are the liver, and the remaining cholesterol in your body is obtained from animal-based diets, including lamb, poultry, and dairy products with dietary cholesterol. It is critical to study this entity, given the multitude of conditions connected to high cholesterol.

Therefore, researchers from prestigious academic institutions have been researching it through cholesterol clinical trials to raise diagnostic accuracy, aid in the diagnosis, and potentially provide treatments.

Why Is Cholesterol Being Studied Through Clinical Trials?

The total cholesterol levels in American adults 20 years of age and older are above 200 mg/dL (normal cholesterol levels are lower than 200mg/dl) in about 94 million people.

In the US, 28 million individuals report having overall cholesterol levels of more than 240 mg/dL. Almost 7% of American adolescents to teenagers between 6 and 19 have high cholesterol levels.

Even though cholesterol is required by the body to create healthy cells, high cholesterol levels significantly raise a person's risk of developing cardiovascular disease. An individual with high cholesterol faces the risk of accumulating fat in the coronary vascular system.

Over time, these fat deposits thicken and restrict the blood that can pass through the arteries. Therefore, it is crucial to conduct cholesterol clinical trials to aid in early detection, diagnosis, prevention, and treatment.

What Are The Types of Treatments Available For Cholesterol?

Cholesterol Absorption Inhibitors

The cholesterol consumed by an individual is absorbed by the small intestine and released into circulation. The medication Ezetimibe lowers blood cholesterol levels by preventing dietary cholesterol from being absorbed. Doctors often prescribe statins in conjunction with Ezetimibe.

Statins

Statins impede the production of the substance that is in charge of producing cholesterol in the liver. When one consumes statins, the liver begins to remove the cholesterol from the blood. There is a multitude of statins on the market, such as Pravachol (Zocor), Atorvastatin (Lipitor), Lovastatin (Altoprev), Rosuvastatin (Crestor), etc.

What Are Some Recent Breakthrough Clinical Trials For Cholesterol?

2021: Efficiency of Leqvio in lowering cholesterol- This study is based on Leqvio, a novel medication, which underwent three recent investigations evaluating its efficacy in treating high cholesterol.  For some high-risk patients using statins, the research trials revealed a decrease of around 40% to 51% in LDL levels when Leqvio was administered to them.

2023: Efficiency of dietary supplements compared to statins- This study demonstrates that frequently utilized dietary supplements claimed to enhance heart health did not decrease bad cholesterol compared with a low dose of a cholesterol-lowering drug called a statin. 

Who Are Some Of The Key Opinion Leaders / Researchers In Cholesterol Clinical Trial Research?

Dr. Paul Clift

Dr. Paul Clift is known for his role as the national specialty lead in cardiovascular disease for the NIHR. He specializes in cardiovascular disease, arrhythmias, and pulmonary arterial hypertension and has contributed to cholesterol clinical trials and conducted several studies on congenital cardiac disease.

Dr Endre Kiss Toth

Dr Endre Kiss Toth is a prominent postdoctoral lead_ _researcher at the University of Sheffield. He and other researchers at the University researched new methods of lowering cholesterol levels in the blood to prevent arteries from getting blocked due to fat buildup.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 13th, 2021

Last Reviewed: August 7th, 2023

References1 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143-421. https://pubmed.ncbi.nlm.nih.gov/124859662 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143-421. No abstract available. https://pubmed.ncbi.nlm.nih.gov/124859663 Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011 Feb 1;123(4):e18-e209. doi: 10.1161/CIR.0b013e3182009701. Epub 2010 Dec 15. Erratum in: Circulation. 2011 Feb 15;123(6):e240. Circulation. 2011 Oct 18;124(16):e426. https://pubmed.ncbi.nlm.nih.gov/211600564 Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011 Feb 1;123(4):e18-e209. doi: 10.1161/CIR.0b013e3182009701. Epub 2010 Dec 15. Erratum In: Circulation. 2011 Feb 15;123(6):e240. Circulation. 2011 Oct 18;124(16):e426. https://pubmed.ncbi.nlm.nih.gov/211600565 Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012 Aug 11;380(9841):565-71. doi: 10.1016/S0140-6736(12)61190-8. https://pubmed.ncbi.nlm.nih.gov/228835076 Warden BA, Duell PB. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. J Cardiovasc Pharmacol. 2021 Aug 1;78(2):e157-e174. doi: 10.1097/FJC.0000000000001053. https://pubmed.ncbi.nlm.nih.gov/339905127 Warden BA, Duell PB. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. J Cardiovasc Pharmacol. 2021 Aug 1;78(2):e157-e174. doi: 10.1097/FJC.0000000000001053. Review. https://pubmed.ncbi.nlm.nih.gov/339905128 Deutz NE, Pereira SL, Hays NP, Oliver JS, Edens NK, Evans CM, Wolfe RR. Effect of β-hydroxy-β-methylbutyrate (HMB) on lean body mass during 10 days of bed rest in older adults. Clin Nutr. 2013 Oct;32(5):704-12. doi: 10.1016/j.clnu.2013.02.011. Epub 2013 Mar 4. https://pubmed.ncbi.nlm.nih.gov/235146269 Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010 Feb 27;375(9716):735-42. doi: 10.1016/S0140-6736(09)61965-6. Epub 2010 Feb 16. https://pubmed.ncbi.nlm.nih.gov/2016735910 Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. 2009 Oct;25(10):567-79. Review. https://pubmed.ncbi.nlm.nih.gov/19812802